Cell & Gene Therapy Manufacturing Services Market

Cell & Gene Therapy Manufacturing Services Market by Type (Allogeneic, Autologous, Viral Vector, Non-viral vector), Indication (Oncology, Orthopedic, Ophthalmology), Application (Clinical, Commercial), End User (Pharma, Biotech) - Global Forecast to 2027

Report Code: BT 7944 Jan, 2023, by marketsandmarkets.com

The global Cell & Gene Therapy Manufacturing Services Market in terms of revenue was estimated to be worth $5.1 billion in 2022 and is poised to reach $11.5 billion by 2027, growing at a CAGR of 17.5% from 2022 to 2027. Growing prevalence of cancer and other other diseases, the surge in pharmaceutical R&D spending along with partnerships and agreements between pharmaceutical companies and CDMOs are some of the factors driving the market growth.  On the contrary, the significant operational costs associated with cell and gene therapy manufacturing is expected to negatively impact the cell & gene therapy manufacturing market during the forecast period.

Attractive opportunities in the Cell & Gene Therapy Manufacturing Services Market

Cell & Gene Therapy Manufacturing Services Market

To know about the assumptions considered for the study, Request for Free Sample Report

Cell & Gene Therapy Manufacturing Services Market Dynamics

Increasing private and public investments in cell and gene therapy industry  

Despite the limited number of approvals, cell and gene therapy companies are attracting an increasing amount of private and public investment. Private equity and capital investment in life sciences have increased rapidly over the last decade. Similarly, the growth of investment in cell and gene therapy companies is also significant. For instance, there is a steep rise in investment from USD 362 million in 2020 to nearly USD 68 billion in 2021. This is expected to increase the demand for outsourcing, thereby increasing the growth of cell and gene therapy manufacturing services.

High operational costs associated with cell & gene therapy manufacturing

Due to the complexity of both the cells (product) and treatment logistics, relatively low production volumes and the large number of manual manipulations involved with current methods, cell therapies are expensive to produce. The manufacturing costs of cell therapy treatments are estimated to be more than USD 100,000 per patient whereas the cost of manufacturing for gene therapy can be between USD 500,000 and USD 1 million, excluding the costs for R&D. Thus, the affordability of cell and gene therapy products will be an important issue and challenge for both manufacturers and healthcare providers..

Expansion of cell and gene therapy manufacturing capacities by CDMOs

Cell and gene therapy manufacturing has evolved rapidly owing to the surge in demand for cell and gene therapies. The wider application of these therapies (for example, to more common diseases) necessitates higher yields and lower product costs (COGs). Large contract development and manufacturing organizations (CDMOs) have made significant investments in this space in recent years, with a number of large acquisitions and geographic expansions by installing production capacities. These expansions will support the manufacturing of cell and gene therapies and provide growth opportunities for CDMOs providing these services.

The cell therapy segment dominated the cell & gene therapy manufacturing services market in 2021.

Based on type, the global market is classified into cell therapy and gene therapy. The cell therapy segment dominated this market with the highest share. The potential applications of cell therapies in the treatment of cancers, autoimmune diseases, urinary problems, and infectious diseases and other diseases is driving the cell therapy segment growth.  In addition availability of funding for new cell lines, increasing organic and inorganic growth strategies by companies  to boost their cell therapy manufacturing capabitlities are some additional factors fueling the segment growth.

Cell & Gene Therapy Manufacturing Services Market by Region

To know about the assumptions considered for the study, download the pdf brochure

North America was the largest regional market for cell & gene therapy manufacturing services market in 2021.

Geographically, the global market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2021, North America accounted for the largest share of this market, followed by Europe and the Asia Pacific. The large share of the North American market is attributed to the rising incidence of cancer and growing research activity in cancer and stem cells.

Key players in the cell & gene therapy manufacturing services market include Lonza (Switzerland), Catalent (US), Thermo Fisher Scientific (US), Charles River Laboratories (US), WuXi AppTec (China), Merck KGaA (Germany), Takara Bio Inc. (Japan), Nikon Corporation (Japan), FUJIFILM Holdings Corporation (Japan), Oxford Biomedica plc (UK), and Cell and Gene Therapy Catapult (UK).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2020–2027

Base year considered

2021

Forecast period

2022–2027

Forecast units

Value (USD) million/Billion

Segments covered

Type, Indication, Application, End User, And Region

Geographies covered

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

Companies covered

Lonza (Switzerland), Catalent, Inc. (US), Thermo Fisher Scientific, Inc. (US), Charles River Laboratories (US), WuXi AppTec (China), Merck KGaA (Germany), Takara Bio Inc. (Japan), Oxford Biomedica (UK), Cell and Gene Therapy Catapult (UK), Genezen (US), FUJIFILM Holdings Corporation (Japan), Nikon Corporation (Japan), The Discovery Labs LLC (US), RoslinCT (Scotland), JRS Pharma (Germany), FinVector (Finland), ABL, Inc. (US), Resilience (US), BioCentriq (US), Porton Advanced Solutions (China), Andelyn Biosciences (US), Forge Biologics (US), Vibalogics (US), Anemocyte Srl (Italy), and ElevateBio (US)

This report categorizes the cell & gene therapy manufacturing services market into the following segments and subsegments

By Type

  • Cell Therapy
    • Allogeneic
      • Mesenchymal Stem Cells
      • T-cells
      • Induced Pluripotent Stem Cells
      • Natural Killer Cells
      • Hematopoietic Stem Cells
      • Other Allogeneic Cells
    • Autologous
      • T-cells
      • Hematopoietic Stem Cells
      • Mesenchymal Stem Cells
      • Natural Killer Cells
      • Other AutologousCells
    • Viral Vector
      • Retroviral Vectors
      • Adeno-associated Virus Vectors
      • Other Viral Vectors
  • Gene Therapy
    • Viral Vector
      • Retroviral Vectors
      • Adeno-associated Virus Vectors
      • Other Viral Vectors
    • Non-viral Vector
      • Oligonucleotides
      • Other Non-viral Vectors

By Indication

  • Oncology Diseases
  • Cardiovascular Diseases
  • Orthopedic Diseases
  • Ophthalmology Diseases
  • Central Nervous System Disorders
  • Infectious Diseases
  • Other Indications

By Application

  • Clinical Manufacturing
  • Commercial Manufacturing

By End User

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • China
    • Japan
    • India
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America (RoLA)
  • Middle East and Africa

Recent Developments

  • In 2021, Charles River Laboratories acquired a cell & gene therapy CDMO—Cognate BioServices—to increase its cell and gene therapy manufacturing capabilities.
  • In 2021, Thermo Fisher Scientific acquired Henogen S.A., Novasep's viral vector manufacturing business in Belgium, for approximately USD 859.7 million. This acquisition will increase its presence in the cell & gene therapy manufacturing therapy market.
  • In 2019, Thermo Fisher Scientific acquired Brammer Bio, a company engaged in viral vector manufacturing for gene and cell therapies, for USD 1.7 billion.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 54)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
          FIGURE 1 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SEGMENTATION
           1.3.1 YEARS CONSIDERED
    1.4 CURRENCY 
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
    1.8 RECESSION IMPACT 
 
2 RESEARCH METHODOLOGY (Page No. - 60)
    2.1 RESEARCH DATA 
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 3 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 4 AVERAGE MARKET SIZE ESTIMATION (2021)
          FIGURE 5 MARKET SIZE ESTIMATION — BOTTOM-UP APPROACH (SUPPLY SIDE): COLLECTIVE REVENUE OF CELL & GENE THERAPY MANUFACTURING SERVICES IN MARKET
          FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021)
    2.3 GROWTH RATE ASSUMPTIONS 
          FIGURE 7 GLOBAL MARKET: CAGR PROJECTIONS
          FIGURE 8 MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 10 DATA TRIANGULATION METHODOLOGY
    2.5 INSIGHTS FROM PRIMARIES 
          FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS
    2.6 RESEARCH ASSUMPTIONS 
    2.7 RISK ANALYSIS 
    2.8 RECESSION IMPACT 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
 
3 EXECUTIVE SUMMARY (Page No. - 73)
    FIGURE 12 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE,2022 VS. 2027 (USD MILLION)
    FIGURE 13 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2022 VS. 2027 (USD MILLION)
    FIGURE 14 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    FIGURE 15 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 16 GEOGRAPHICAL SNAPSHOT OF CELL & GENE THERAPY MANUFACTURING SERVICES MARKET
 
4 PREMIUM INSIGHTS (Page No. - 77)
    4.1 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET OVERVIEW 
          FIGURE 17 HIGH INCIDENCE OF CANCER AND OTHER TARGET DISEASES TO DRIVE MARKET
    4.2 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE AND COUNTRY (2022) 
          FIGURE 18 CELL THERAPY SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
    4.3 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE, BY TYPE, 2022 VS. 2027 
          FIGURE 19 CELL THERAPY SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2027
    4.4 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE, BY END USER, 2021 
          FIGURE 20 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2021
    4.5 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 21 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH IN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FROM 2022 TO 2027
 
5 MARKET OVERVIEW (Page No. - 80)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 22 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          TABLE 2 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 High incidence of cancer and other target diseases
                                TABLE 3 FDA-APPROVED CAR T-CELL THERAPIES
                    5.2.1.2 Increasing pharmaceutical R&D spending
                                FIGURE 23 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026
                    5.2.1.3 Increasing private and public investments in cell and gene therapy industry
                    5.2.1.4 Technological advancements
                                TABLE 4 TECHNOLOGIES OFFERED BY CELL & GENE THERAPY MANUFACTURING SERVICE PROVIDERS
                    5.2.1.5 Increasing partnerships and agreements between pharmaceutical companies and CDMOs
                                TABLE 5 PARTNERSHIPS BETWEEN PHARMACEUTICAL COMPANIES AND CDMOS
           5.2.2 RESTRAINTS
                    5.2.2.1 High operational costs associated with cell & gene therapy manufacturing
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Expansion of cell and gene therapy manufacturing capacities by CDMOs
                                TABLE 6 MANUFACTURING CAPACITY EXPANSIONS BY CDMOS
                    5.2.3.2 Growing cell & gene therapies market
           5.2.4 CHALLENGES
                    5.2.4.1 Risk of mutagenesis
                    5.2.4.2 Low yield outcomes
                    5.2.4.3 Lack of standard production systems
    5.3 TECHNOLOGICAL ANALYSIS 
    5.4 RANGES/SCENARIOS 
          FIGURE 24 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF CELL & GENE THERAPY MANUFACTURING SERVICES MARKET
    5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 
          FIGURE 25 REVENUE SHIFT AND NEW POCKETS FOR CELL & GENE THERAPY MANUFACTURING SERVICE PROVIDERS
    5.6 VALUE CHAIN ANALYSIS 
          FIGURE 26 VALUE CHAIN ANALYSIS OF CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: HARVESTING AND CRYOPRESERVATION PHASES ADD MAXIMUM VALUE
    5.7 ECOSYSTEM ANALYSIS OF CELL & GENE THERAPY MANUFACTURING SERVICES MARKET 
          FIGURE 27 ECOSYSTEM ANALYSIS OF CELL & GENE THERAPY MANUFACTURING SERVICES MARKET
          TABLE 7 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET ECOSYSTEM
    5.8 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 8 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.8.1 THREAT OF NEW ENTRANTS
           5.8.2 THREAT OF SUBSTITUTES
           5.8.3 BARGAINING POWER OF BUYERS
           5.8.4 BARGAINING POWER OF SUPPLIERS
           5.8.5 INTENSITY OF COMPETITIVE RIVALRY
    5.9 REGULATORY ANALYSIS 
           5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 12 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 13 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.10 KEY CONFERENCES AND EVENTS IN 2022–2023 
           TABLE 14 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: LIST OF CONFERENCES AND EVENTS
    5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 
           FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CELL & GENE THERAPY MANUFACTURING SERVICES
    5.12 KEY BUYING CRITERIA 
           FIGURE 29 BUYING CRITERIA OF END USERS FOR CELL & GENE THERAPY MANUFACTURING SERVICES
 
6 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE (Page No. - 103)
    6.1 INTRODUCTION 
          TABLE 15 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
    6.2 CELL THERAPY 
          TABLE 16 CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 17 CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
          TABLE 18 NORTH AMERICA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 19 EUROPE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 20 ASIA PACIFIC: CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 21 LATIN AMERICA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           6.2.1 ALLOGENEIC
                    TABLE 22 ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 23 ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 24 NORTH AMERICA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 25 EUROPE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 26 ASIA PACIFIC: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 27 LATIN AMERICA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.2.1.1 Mesenchymal stem cells
                               6.2.1.1.1 Immunosuppressive and tissue repair properties to support market growth
                                              TABLE 28 ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                                              TABLE 29 NORTH AMERICA: ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 30 EUROPE: ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 31 ASIA PACIFIC: ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 32 LATIN AMERICA: ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.2.1.2 T-cells
                               6.2.1.2.1 Generated by virus transduction and in vitro expansion before patient administration
                                              TABLE 33 ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                                              TABLE 34 NORTH AMERICA: ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 35 EUROPE: ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 36 ASIA PACIFIC: ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 37 LATIN AMERICA: ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.2.1.3 Induced pluripotent stem cells
                               6.2.1.3.1 Growing adoption of IPSCs in research to drive market
                                              TABLE 38 ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                                              TABLE 39 NORTH AMERICA: ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 40 EUROPE: ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 41 ASIA PACIFIC: ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 42 LATIN AMERICA: ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.2.1.4 Natural killer cells
                               6.2.1.4.1 Used for advanced hepatocellular carcinoma patients
                                              TABLE 43 ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                                              TABLE 44 NORTH AMERICA: ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 45 EUROPE: ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 46 ASIA PACIFIC: ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 47 LATIN AMERICA: ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.2.1.5 Hematopoietic stem cells
                               6.2.1.5.1 Stem cells from donors used for allogeneic transplantation
                                              TABLE 48 ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                                              TABLE 49 NORTH AMERICA: ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 50 EUROPE: ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 51 ASIA PACIFIC: ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 52 LATIN AMERICA: ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.2.1.6 Other allogeneic cells
                                TABLE 53 OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 54 NORTH AMERICA: OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 55 EUROPE: OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 56 ASIA PACIFIC: OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 57 LATIN AMERICA: OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           6.2.2 AUTOLOGOUS
                    TABLE 58 AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 59 AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 60 NORTH AMERICA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 61 EUROPE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 62 ASIA PACIFIC: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 63 LATIN AMERICA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.2.2.1 T-cells
                               6.2.2.1.1 Major components of adaptive immune system
                                              TABLE 64 AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                                              TABLE 65 NORTH AMERICA: AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 66 EUROPE: AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 67 ASIA PACIFIC: AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 68 LATIN AMERICA: AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.2.2.2 Hematopoietic stem cells
                               6.2.2.2.1 Used to establish marrow and bone function
                                              TABLE 69 AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                                              TABLE 70 NORTH AMERICA: AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 71 EUROPE: AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 72 ASIA PACIFIC: AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 73 LATIN AMERICA: AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.2.2.3 Mesenchymal stem cells
                               6.2.2.3.1 Present in umbilical cord, bone marrow, and fat tissue
                                              TABLE 74 AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                                              TABLE 75 NORTH AMERICA: AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 76 EUROPE: AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 77 ASIA PACIFIC: AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 78 LATIN AMERICA: AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.2.2.4 Natural killer cells
                               6.2.2.4.1 Used in treatment of tumors and infectious diseases
                                              TABLE 79 AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                                              TABLE 80 NORTH AMERICA: AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 81 EUROPE: AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 82 ASIA PACIFIC: AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 83 LATIN AMERICA: AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.2.2.5 Other autologous cells
                                TABLE 84 OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 85 NORTH AMERICA: OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 86 EUROPE: OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 87 ASIA PACIFIC: OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 88 LATIN AMERICA: OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           6.2.3 VIRAL VECTORS
                    TABLE 89 VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 90 VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 91 NORTH AMERICA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 92 EUROPE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 93 ASIA PACIFIC: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 94 LATIN AMERICA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.2.3.1 Retroviral vectors
                               6.2.3.1.1 Most used viral vector for cell therapy manufacturing
                                              TABLE 95 RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                                              TABLE 96 NORTH AMERICA: RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 97 EUROPE: RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 98 ASIA PACIFIC: RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 99 LATIN AMERICA: RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.2.3.2 Adeno-associated virus vectors
                               6.2.3.2.1 AAV vector-based techniques used for CAR T-cell therapy development
                                              TABLE 100 ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                                              TABLE 101 NORTH AMERICA: ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 102 EUROPE: ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 103 ASIA PACIFIC: ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 104 LATIN AMERICA: ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.2.3.3 Other viral vectors
                                TABLE 105 OTHER VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 106 NORTH AMERICA: OTHER VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 107 EUROPE: OTHER VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 108 ASIA PACIFIC: OTHER VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 109 LATIN AMERICA: OTHER VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3 GENE THERAPY 
          TABLE 110 GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION)
          TABLE 111 GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
          TABLE 112 NORTH AMERICA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 113 EUROPE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 114 ASIA PACIFIC: GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 115 LATIN AMERICA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           6.3.1 VIRAL VECTORS
                    TABLE 116 VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 117 VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 118 NORTH AMERICA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 119 EUROPE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 120 ASIA PACIFIC: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 121 LATIN AMERICA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.3.1.1 Retroviral vectors
                               6.3.1.1.1 Retroviral vectors possess ability to replicate within cells
                                              TABLE 122 RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                                              TABLE 123 NORTH AMERICA: RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 124 EUROPE: RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 125 ASIA PACIFIC: RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 126 LATIN AMERICA: RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.3.1.2 Adeno-associated virus vectors
                               6.3.1.2.1 Small, single-stranded DNA viruses with low toxicity
                                              TABLE 127 ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                                              TABLE 128 NORTH AMERICA: ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 129 EUROPE: ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 130 ASIA PACIFIC: ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 131 LATIN AMERICA: ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.3.1.3 Other viral vectors
TABLE 132 OTHER VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 133 NORTH AMERICA: OTHER VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 134 EUROPE: OTHER VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 135 ASIA PACIFIC: OTHER VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 136 LATIN AMERICA: OTHER VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           6.3.2 NON-VIRAL VECTORS
                    TABLE 137 NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 138 NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 139 NORTH AMERICA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 140 EUROPE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 141 ASIA PACIFIC: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 142 LATIN AMERICA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.3.2.1 Oligonucleotides
                               6.3.2.1.1 North America accounted for largest share of oligonucleotides market in 2021
                                              TABLE 143 OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                                              TABLE 144 NORTH AMERICA: OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 145 EUROPE: OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 146 ASIA PACIFIC: OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                              TABLE 147 LATIN AMERICA: OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    6.3.2.2 Other non-viral vectors
                                TABLE 148 OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 149 NORTH AMERICA: OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 150 EUROPE: OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 151 ASIA PACIFIC: OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 152 LATIN AMERICA: OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
 
7 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION (Page No. - 162)
    7.1 INTRODUCTION 
          TABLE 153 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION)
    7.2 ONCOLOGY DISEASES 
           7.2.1 RISING NUMBER OF CANCER CASES WORLDWIDE TO DRIVE DEMAND FOR CELL & GENE THERAPIES
                    TABLE 154 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 155 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 156 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 157 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 158 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
    7.3 CARDIOVASCULAR DISEASES 
           7.3.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES OWING TO SEDENTARY LIFESTYLES TO DRIVE MARKET
                    TABLE 159 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 160 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 161 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 162 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 163 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
    7.4 ORTHOPEDIC DISEASES 
           7.4.1 CELL THERAPY FOR ORTHOPEDIC DISEASES ELIMINATES POST-TREATMENT COMPLICATIONS
                    TABLE 164 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 165 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 166 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 167 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 168 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
    7.5 OPHTHALMOLOGY DISEASES 
           7.5.1 STEM CELL THERAPIES USED FOR RESTORATION AND PRESERVATION OF VISION
                    TABLE 169 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPHTHALMOLOGY DISEASES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 170 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPHTHALMOLOGY DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 171 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPHTHALMOLOGY DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 172 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPHTHALMOLOGY DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 173 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPHTHALMOLOGY DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
    7.6 CENTRAL NERVOUS SYSTEM DISORDERS 
           7.6.1 INCREASING INCIDENCE OF SPINAL MUSCULAR ATROPHY TO SUPPORT MARKET GROWTH
                    TABLE 174 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 175 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 176 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 177 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 178 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.7 INFECTIOUS DISEASES 
           7.7.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
                    TABLE 179 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 180 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 181 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 182 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 183 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
    7.8 OTHER INDICATIONS 
          TABLE 184 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY REGION, 2020–2027 (USD MILLION)
          TABLE 185 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 186 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 187 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 188 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
 
8 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION (Page No. - 179)
    8.1 INTRODUCTION 
          TABLE 189 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
    8.2 CLINICAL MANUFACTURING 
           8.2.1 RISING NUMBER OF CLINICAL TRIALS FOR CELL & GENE THERAPIES TO DRIVE MARKET
                    TABLE 190 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 191 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 192 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 193 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 194 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION)
    8.3 COMMERCIAL MANUFACTURING 
           8.3.1 INCREASING APPROVALS OF CELL & GENE THERAPY PRODUCTS FOR COMMERCIAL MANUFACTURING TO SUPPORT MARKET GROWTH
                    TABLE 195 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 196 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 197 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 198 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 199 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION)
 
9 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER (Page No. - 185)
    9.1 INTRODUCTION 
          TABLE 200 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
           9.2.1 GROWING NUMBER OF CELL & GENE THERAPIES IN R&D PIPELINE TO DRIVE MARKET
                    TABLE 201 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 202 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 203 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 204 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 205 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
    9.3 ACADEMIC & RESEARCH INSTITUTES 
           9.3.1 INCREASE IN LIFE SCIENCES R&D EXPENDITURE TO SUPPORT MARKET GROWTH
                    TABLE 206 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 207 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 208 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 209 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 210 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
    9.4 OTHER END USERS 
          TABLE 211 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
          TABLE 212 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 213 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 214 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 215 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION)
 
10 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION (Page No. - 194)
     10.1 INTRODUCTION 
            TABLE 216 CELL & GENE THERAPY MANUFACTURING THERAPY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
     10.2 NORTH AMERICA 
             10.2.1 RECESSION IMPACT
                        FIGURE 30 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SNAPSHOT
                        TABLE 217 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                        TABLE 218 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 219 NORTH AMERICA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 220 NORTH AMERICA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 221 NORTH AMERICA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 222 NORTH AMERICA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 223 NORTH AMERICA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                        TABLE 224 NORTH AMERICA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 225 NORTH AMERICA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 226 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                        TABLE 227 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 228 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.2.2 US
                        10.2.2.1 Rising prevalence of cancer and increasing clinical trials for cell and gene therapies to drive market
                                      TABLE 229 US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 230 US: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 231 US: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 232 US: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 233 US: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 234 US: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                                      TABLE 235 US: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 236 US: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 237 US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                      TABLE 238 US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 239 US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.2.3 CANADA
                        10.2.3.1 Increasing investments in stem cell research to support market
                                      TABLE 240 CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 241 CANADA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 242 CANADA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 243 CANADA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 244 CANADA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 245 CANADA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                                      TABLE 246 CANADA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 247 CANADA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 248 CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                      TABLE 249 CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 250 CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
     10.3 EUROPE 
             10.3.1 RECESSION IMPACT
                        TABLE 251 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                        TABLE 252 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 253 EUROPE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 254 EUROPE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 255 EUROPE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 256 EUROPE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 257 EUROPE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                        TABLE 258 EUROPE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 259 EUROPE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 260 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                        TABLE 261 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 262 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.2 GERMANY
                        10.3.2.1 Strong growth in biotechnology industry to drive market
                                      TABLE 263 GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 264 GERMANY: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 265 GERMANY: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 266 GERMANY: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 267 GERMANY: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 268 GERMANY: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                                      TABLE 269 GERMANY: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 270 GERMANY: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 271 GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                      TABLE 272 GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 273 GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.3 UK
                        10.3.3.1 Rising funding and growing prevalence of chronic diseases to drive market
                                      TABLE 274 UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 275 UK: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 276 UK: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 277 UK: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 278 UK: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 279 UK: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                                      TABLE 280 UK: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 281 UK: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 282 UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                      TABLE 283 UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 284 UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.4 FRANCE
                        10.3.4.1 Availability of funds from government and private organizations to support market
                                      TABLE 285 FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 286 FRANCE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 287 FRANCE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 288 FRANCE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 289 FRANCE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 290 FRANCE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                                      TABLE 291 FRANCE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 292 FRANCE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 293 FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                      TABLE 294 FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 295 FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.5 ITALY
                        10.3.5.1 Recent developments in cell and gene therapy to drive market
                                      TABLE 296 ITALY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 297 ITALY: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 298 ITALY: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 299 ITALY: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 300 ITALY: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 301 ITALY: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                                      TABLE 302 ITALY: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 303 ITALY: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 304 ITALY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                      TABLE 305 ITALY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 306 ITALY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.6 SPAIN
                        10.3.6.1 Rising R&D expenditure to boost market
                                      TABLE 307 SPAIN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 308 SPAIN: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 309 SPAIN: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 310 SPAIN: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 311 SPAIN: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 312 SPAIN: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                                      TABLE 313 SPAIN: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 314 SPAIN: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 315 SPAIN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                      TABLE 316 SPAIN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 317 SPAIN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.7 REST OF EUROPE
                        TABLE 318 REST OF EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 319 REST OF EUROPE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 320 REST OF EUROPE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 321 REST OF EUROPE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 322 REST OF EUROPE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 323 REST OF EUROPE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                        TABLE 324 REST OF EUROPE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 325 REST OF EUROPE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 326 REST OF EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                        TABLE 327 REST OF EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 328 REST OF EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
     10.4 ASIA PACIFIC 
             10.4.1 RECESSION IMPACT
                        FIGURE 31 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SNAPSHOT
                        TABLE 329 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                        TABLE 330 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 331 ASIA PACIFIC: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 332 ASIA PACIFIC: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 333 ASIA PACIFIC: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 334 ASIA PACIFIC: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 335 ASIA PACIFIC: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                        TABLE 336 ASIA PACIFIC: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 337 ASIA PACIFIC: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 338 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                        TABLE 339 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 340 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.4.2 CHINA
                        10.4.2.1 Increasing government funding and development of novel applications to drive market
                                      TABLE 341 CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 342 CHINA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 343 CHINA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 344 CHINA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 345 CHINA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 346 CHINA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                                      TABLE 347 CHINA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 348 CHINA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 349 CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                      TABLE 350 CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 351 CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.4.3 JAPAN
                        10.4.3.1 Robust funding coupled with growing geriatric population to propel market growth
                                      TABLE 352 JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 353 JAPAN: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 354 JAPAN: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 355 JAPAN: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 356 JAPAN: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 357 JAPAN: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                                      TABLE 358 JAPAN: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 359 JAPAN: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 360 JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                      TABLE 361 JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 362 JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.4.4 INDIA
                        10.4.4.1 Growing prevalence of chronic diseases and focus on grants and collaborations for research to drive market
                                      TABLE 363 INDIA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 364 INDIA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 365 INDIA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 366 INDIA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 367 INDIA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 368 INDIA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                                      TABLE 369 INDIA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 370 INDIA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 371 INDIA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                      TABLE 372 INDIA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 373 INDIA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.4.5 REST OF ASIA PACIFIC
                        TABLE 374 REST OF ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 375 REST OF ASIA PACIFIC: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 376 REST OF ASIA PACIFIC: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 377 REST OF ASIA PACIFIC: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 378 REST OF ASIA PACIFIC: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 379 REST OF ASIA PACIFIC: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                        TABLE 380 REST OF ASIA PACIFIC: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 381 REST OF ASIA PACIFIC: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 382 REST OF ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                        TABLE 383 REST OF ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 384 REST OF ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
     10.5 LATIN AMERICA 
             10.5.1 RECESSION IMPACT
                        TABLE 385 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                        TABLE 386 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 387 LATIN AMERICA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 388 LATIN AMERICA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 389 LATIN AMERICA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 390 LATIN AMERICA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 391 LATIN AMERICA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                        TABLE 392 LATIN AMERICA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 393 LATIN AMERICA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 394 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                        TABLE 395 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 396 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.5.2 BRAZIL
                        10.5.2.1 Gradual increase in pharmaceutical R&D to support market
                                      TABLE 397 BRAZIL: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 398 BRAZIL: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 399 BRAZIL: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 400 BRAZIL: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 401 BRAZIL: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 402 BRAZIL: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                                      TABLE 403 BRAZIL: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 404 BRAZIL: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 405 BRAZIL: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                      TABLE 406 BRAZIL: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 407 BRAZIL: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.5.3 MEXICO
                        10.5.3.1 Favorable government policies in Mexico to support market
                                      TABLE 408 MEXICO: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 409 MEXICO: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 410 MEXICO: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 411 MEXICO: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 412 MEXICO: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 413 MEXICO: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                                      TABLE 414 MEXICO: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 415 MEXICO: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 416 MEXICO: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                      TABLE 417 MEXICO: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 418 MEXICO: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.5.4 REST OF LATIN AMERICA
                        TABLE 419 REST OF LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 420 REST OF LATIN AMERICA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 421 REST OF LATIN AMERICA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 422 REST OF LATIN AMERICA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 423 REST OF LATIN AMERICA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 424 REST OF LATIN AMERICA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                        TABLE 425 REST OF LATIN AMERICA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 426 REST OF LATIN AMERICA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 427 REST OF LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                        TABLE 428 REST OF LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 429 REST OF LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA 
             10.6.1 CHANGING DEMOGRAPHICS AND FAVORABLE POLICIES FOR PHARMACEUTICAL R&D TO DRIVE MARKET
             10.6.2 RECESSION IMPACT
                        TABLE 430 MIDDLE EAST & AFRICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 431 MIDDLE EAST & AFRICA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 432 MIDDLE EAST & AFRICA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 433 MIDDLE EAST & AFRICA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 434 MIDDLE EAST & AFRICA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 435 MIDDLE EAST & AFRICA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION)
                        TABLE 436 MIDDLE EAST & AFRICA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 437 MIDDLE EAST & AFRICA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 438 MIDDLE EAST & AFRICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                        TABLE 439 MIDDLE EAST & AFRICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 440 MIDDLE EAST & AFRICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
 
11 COMPETITIVE LANDSCAPE (Page No. - 289)
     11.1 OVERVIEW 
     11.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             FIGURE 32 KEY PLAYER STRATEGIES IN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, 2019–2022
     11.3 MARKET SHARE ANALYSIS 
             FIGURE 33 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2021
             TABLE 441 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: DEGREE OF COMPETITION
     11.4 REVENUE SHARE ANALYSIS 
             FIGURE 34 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS
     11.5 COMPANY EVALUATION QUADRANT 
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 35 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: COMPANY EVALUATION QUADRANT, 2021
     11.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES 
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
                        FIGURE 36 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2021
     11.7 COMPETITIVE BENCHMARKING OF STARTUPS/SMES 
             TABLE 442 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
             TABLE 443 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
     11.8 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 
             11.8.1 COMPANY FOOTPRINT
                        TABLE 444 COMPANY FOOTPRINT ANALYSIS OF KEY PLAYERS
             11.8.2 SERVICE FOOTPRINT
                        TABLE 445 SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS
             11.8.3 APPLICATION FOOTPRINT
                        TABLE 446 APPLICATION FOOTPRINT ANALYSIS OF KEY PLAYERS
             11.8.4 REGIONAL FOOTPRINT
                        TABLE 447 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
     11.9 COMPETITIVE SCENARIO AND TRENDS 
             11.9.1 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: DEALS, JANUARY 2019–DECEMBER 2022
             11.9.2 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2019–DECEMBER 2022
             11.9.3 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: OTHER DEVELOPMENTS, JANUARY 2019–DECEMBER 2022
 
12 COMPANY PROFILES (Page No. - 305)
     12.1 KEY MARKET PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             12.1.1 LONZA
                        TABLE 448 LONZA: BUSINESS OVERVIEW
                        FIGURE 37 LONZA: COMPANY SNAPSHOT (2021)
             12.1.2 CATALENT, INC.
                        TABLE 449 CATALENT, INC.: BUSINESS OVERVIEW
                        FIGURE 38 CATALENT, INC.: COMPANY SNAPSHOT (2021)
             12.1.3 THERMO FISHER SCIENTIFIC, INC.
                        TABLE 450 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                        FIGURE 39 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
             12.1.4 MERCK KGAA
                        TABLE 451 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 40 MERCK KGAA: COMPANY SNAPSHOT (2021)
             12.1.5 CHARLES RIVER LABORATORIES
                        TABLE 452 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 41 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2021)
             12.1.6 TAKARA BIO INC.
                        TABLE 453 TAKARA BIO INC.: BUSINESS OVERVIEW
                        FIGURE 42 TAKARA BIO INC.: COMPANY SNAPSHOT (2021)
             12.1.7 OXFORD BIOMEDICA PLC
                        TABLE 454 OXFORD BIOMEDICA PLC: BUSINESS OVERVIEW
                        FIGURE 43 OXFORD BIOMEDICA PLC: COMPANY SNAPSHOT (2021)
             12.1.8 CELL AND GENE THERAPY CATAPULT
                        TABLE 455 CELL AND GENE THERAPY CATAPULT: BUSINESS OVERVIEW
                        FIGURE 44 CELL AND GENE THERAPY CATAPULT: COMPANY SNAPSHOT (2021)
             12.1.9 FUJIFILM HOLDINGS CORPORATION
                        TABLE 456 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
                        FIGURE 45 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021)
             12.1.10 WUXI APPTEC
                        TABLE 457 WUXI APPTEC: BUSINESS OVERVIEW
                        FIGURE 46 WUXI APPTEC: COMPANY SNAPSHOT (2021)
             12.1.11 NIKON CORPORATION
                        TABLE 458 NIKON CORPORATION: BUSINESS OVERVIEW
                        FIGURE 47 NIKON CORPORATION: COMPANY SNAPSHOT (2021)
     12.2 OTHER PLAYERS 
             12.2.1 THE DISCOVERY LABS
             12.2.2 ROSLINCT
             12.2.3 JRS PHARMA
             12.2.4 FINVECTOR
             12.2.5 ABL, INC.
             12.2.6 RESILIENCE, INC.
             12.2.7 BIOCENTRIQ
             12.2.8 PORTON ADVANCED SOLUTIONS
             12.2.9 ANDELYN BIOSCIENCES
             12.2.10 GENEZEN
             12.2.11 VIBALOGICS
             12.2.12 ANEMOCYTE SRL
             12.2.13 ELEVATE BIO
             12.2.14 FORGE BIOLOGICS
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 367)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the cell & gene therapy manufacturing services market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the cell & gene therapy manufacturing services market. The secondary sources used for this study include Some of the key secondary sources referred to for this study include the American Society of Gene & Cell Therapy (ASGCT), Centers for Disease Control and Prevention (CDC), GLOBOCAN, World Health Organization (WHO), US Food and Drug Administration (FDA), National Institutes of Health (NIH), European Union (EU), National Stem Cell Foundation, International Society for Cell & Gene Therapy (ISCT), EuroStemCell, European Society of Gene and Cell Therapy, Japan Human Cell Society, Indian Pharmaceutical Association (IPA), Pharmaceutical Research and Manufacturers of America (PhRMA), and European Federation of Pharmaceutical Industries and Associations (EFPIA). These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Cell & Gene Therapy Manufacturing Services Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the cell & gene therapy manufacturing services market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the cell & gene therapy manufacturing services business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the global cell & gene therapy manufacturing services market based on the type, indication, application, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, opportunities, and trends)
  • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall cell & gene therapy manufacturing services market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product/service launches, expansions, agreements, partnerships, and R&D activities in the cell & gene therapy manufacturing services market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

  • An additional five company profiles
Report Code
BT 7944
Published ON
Jan, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Cell & Gene Therapy Manufacturing Services Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback